According to FutureWise analysis the fibrin sealant market in 2025 is US$ 1341 million, and is expected to reach US$ 2806 million by 2033 at a CAGR of 9.67%. The growth of the market for fibrin sealants is largely attributed to their increasing use in surgical procedures designed to reduce blood loss and promote wound healing. Additionally, the growing preference for minimally invasive surgeries, along with advancements in biocompatible hemostatic agents, is contributing to this expansion.
Fibrin sealant is a biological agent that is used to control bleeding in surgeries or injuries where ligation, suturing or cautery does not provide enough haemostasis. Fibrin is a mixture of thrombin or fibrinogen which is applied to the affected area in order to prevent haemorrhage. Additionally, a permanent factor for regional growth is also delivered by fibrin as it is also used as a delivery device. It is also an excellent blood clotting agent and it can also do tissue sealing so that it can prevent serious fluid accumulation or lymphatic leak. Considering all these properties, fibrin sealant is an ideal component for reducing fluid accumulation, ecchymoses, hematomas, swelling etc. Perhaps, it also eliminates the need for drains after rhytidectomy.
Fibrin sealant market is primarily driven by increasing prevalence of invasive surgeries and traumatic injuries. Recent advancements have led to the development of biocompatible sealants which decreased the complications and allow normal movement of tissues without any interference on the functioning of the organs. Traditionally, sutures/wires/staples are used for wound sealing and they pose significant threats like tissue damage, infection and delayed the repair of the tissue. Due to the rapid advancements of technologies, traditional methods are replaced by sealants and let to the burgeoning growth of the market. Among the different types of sealants, synthetic adhesives offer high mechanical and adhesive strength. These features made the synthetic surgical sealants most attractive segment over natural sealants and expected to witness significant growth during the forecast period. All these factors have led to the potential growth of the market.
Recombinant & Bioengineered Formulations: Increased use of recombinant fibrinogen and thrombin reduces reliance on pooled human or animal plasma. This change improves consistency, reduces the risk of transmissible disease, and addresses immunogenicity concerns.
Development of autologous fibrin sealants from the patient’s own blood improves biocompatibility and reduces immune rejection.
Advanced Delivery / Application Systems: Airless spray delivery systems provide more uniform coverage, making them useful in minimally invasive laparoscopic and robotic surgeries.